Collaboration Value TILT's oncolytic virus platform enhances TILs, CAR-T, and immune checkpoint therapies, with a lead asset and a Merck collaboration already in place. This creates clear sales opportunities for co-development, licensing, or out-licensing the platform to pharma and biotech partners aiming to strengthen combination immunotherapies across multiple solid tumor indications.

Funding Momentum The company has secured notable funding and grants, including venture rounds and a DoD grant, signaling investor and programmatic interest. This financial momentum supports structured partnership deals with upfronts and milestones, as well as grant-funded collaborative trials that can de-risk early-stage engagements for potential partners.

Global Footprint Expansion into the US with a Boston office demonstrates a commitment to US clinical development and partnership activity, presenting BD opportunities to engage pharma, CROs, and academic partners for joint trials, regulatory support, and US-based manufacturing or supply chain collaborations.

Tech Platform Lead candidate TILT-123 (TNFα/IL2 armed oncolytic adenovirus) positions the company as a platform enabler for enhancing multiple cell and antibody therapies. This broadens sales angles to license or co-develop across ovarian cancer and other solid tumors, leveraging immune-oncology trends.

Partner Targeting A track record of collaboration with Merck and active Phase I programs indicate viability for deeper partnerships. Potential sales plays include licensing the platform, contract research or manufacturing services, and strategic alliances to accelerate clinical development and geographic expansion.